President, House agitate for more drug cuts

Big Pharma's $80 billion cost-cutting deal with Washington isn't as comprehensive as the industry had hoped. In last night's news conference, President Obama suggested, "We might be able to get $100 billion out of them, or more." And that's just the beginning. Rep. Henry A. Waxman, has proposed a $63 billion cut in drug spending, achieved by reversing a 2006 policy that took low-income elderly folks out of Medicaid drug coverage and added them to Medicare, which pays more.

And then there's generic competition for biologics. The Senate may be working on a bill with 12-year exclusivity for branded versions of the pricey drugs, but Waxman advocates only 5-year exclusivity. Obama backs a 7-year protection plan. And Waxman chairs the House Energy and Commerce Committee, which is spearheading healthcare reform in the House.

"I know they have a deal with the Senate," Waxman told the New York Times, "and I think they do have a deal with the White House, but I don't know how pinned down it all is. But they don't have a deal with us--the House." So PhRMA chief Billy Tauzin is working on that: The NYT reports that he met last weekend with the Blue Dog Democrats, who control key votes on Waxman's committee. We'll have to wait and see how that goes.

- read the NYT story

ALSO: President Obama's administration began holding private meetings with health industry executives--including Johnson & Johnson CEO Bill Weldon, Pfizer chief Jeff Kindler, and Merck CEO Dick Clark--at the White House a few weeks after he took office. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.